A new option for post-CDK4/6is resistance era? Multicenter real-world study of anlotinib-based combination therapy in hormone receptor-positive metastatic breast cancer resistant to CDK4/6 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results